MARKET INSIGHTS
Global (S)-1-Cyclohexylethylamine (CAS 17430-98-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.
(S)-1-Cyclohexylethylamine (CAS 17430-98-7) is a chiral amine compound characterized by a cyclohexyl group attached to an ethylamine backbone in its (S)-enantiomeric configuration. This specialty chemical serves as a critical building block and chiral auxiliary in asymmetric synthesis, pharmaceutical manufacturing, and agrochemical development. Its high enantiomeric purity makes it particularly valuable in the production of optically active intermediates used across drug discovery pipelines.
The market is gaining momentum primarily because of the expanding demand for enantiomerically pure compounds in pharmaceutical synthesis, where regulatory bodies increasingly require single‑enantiomer drugs over racemic mixtures. Furthermore, growing investment in chiral chemistry research and the rising adoption of this compound as a resolving agent and ligand precursor are reinforcing market expansion. Key suppliers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, among other fine chemical manufacturers with established chiral amine portfolios.
(S)-1-Cyclohexylethylamine (CAS 17430-98-7) Market – View in Detailed Research Report
Top 10 Companies in the (S)-1-Cyclohexylethylamine Market
1. BASF SE
Headquarters: Ludwigshafen, Germany
Key Offering: Pharmaceutical‑grade chiral amines and advanced process chemistry solutions
BASF leverages its global research network and cGMP‑compliant facilities to deliver high‑purity (S)-1‑cyclohexylethylamine to leading pharmaceutical clients. The company’s focus on scalable, atom‑efficient processes reduces waste and aligns with the sustainability expectations of major drug developers.
Sustainability & Growth Initiatives: Investment in green chemistry protocols and the adoption of renewable feedstocks for chiral amine synthesis.
- Renewable raw‑material sourcing
- Process intensification to cut solvent use
- Collaborations with academic partners on biocatalytic routes
2. Evonik Industries AG
Headquarters: Essen, Germany
Key Offering: High‑purity chiral intermediates and custom synthesis services
Evonik’s dedicated fine‑chemical division provides tailored solutions for API manufacturers, ensuring consistent optical purity and traceability. Its integrated quality management system supports rapid regulatory approvals.
Sustainability & Growth Initiatives: Development of low‑energy catalytic processes and partnership with bio‑engineering firms.
- Energy‑efficient hydrogenation units
- Biocatalytic enzyme libraries for chiral amines
- Carbon‑neutral production targets by 2035
3. Jiangsu Hengrui Medicine Co., Ltd.
Headquarters: Nanjing, China
Key Offering: Bulk chiral amine production for API synthesis
Hengrui’s large‑scale synthesis capacity positions it as a primary supplier to the rapidly expanding Chinese pharma sector. The company’s investment in quality control infrastructure ensures compliance with international GMP standards.
Sustainability & Growth Initiatives: Implementation of closed‑loop water systems and waste‑recycling programs.
- Zero‑liquid‑discharge (ZLD) technology
- Process‑water reuse across all units
- Environmental Impact Assessment (EIA) certification
4. Shandong Xinhua Pharmaceutical Co., Ltd.
Headquarters: Qiqihar, China
Key Offering: Pharmaceutical‑grade chiral amines and API development support
Shandong Xinhua’s strategic partnerships with leading pharma companies enable it to supply high‑purity intermediates at competitive prices while maintaining rigorous quality standards.
Sustainability & Growth Initiatives: Adoption of green solvent alternatives and digital process monitoring.
- Supercritical CO₂ extraction for purification
- Real‑time analytics for batch consistency
- Carbon‑footprint tracking dashboard
5. TCI Chemicals
Headquarters: Tokyo, Japan
Key Offering: Research‑grade chiral amines and catalog‑grade supplies
TCI serves academic and industrial researchers with high‑purity (S)-1‑cyclohexylethylamine, supporting early‑stage drug discovery and catalyst development.
Sustainability & Growth Initiatives: Focus on low‑toxicity reagents and waste‑minimization protocols.
- Eco‑friendly solvent blends
- Waste‑to‑energy conversion projects
- Supplier sustainability scorecards
6. Alfa Chemistry
Headquarters: Billerica, USA
Key Offering: Custom synthesis and small‑batch chiral amines
Alfa Chemistry’s flexible manufacturing model caters to niche pharma and biotech clients, delivering high‑quality intermediates with rapid turnaround times.
Sustainability & Growth Initiatives: Integration of modular biocatalytic units and renewable energy sourcing.
- Modular flow‑chemistry reactors
- Solar‑powered facility upgrades
- Carbon‑offset partnership with local NGOs
7. Hangzhou Dayangchem Co., Ltd.
Headquarters: Hangzhou, China
Key Offering: Mid‑volume chiral amines and specialty intermediates
Dayangchem’s focus on cost efficiency and rapid scale‑up makes it an attractive partner for generic API producers.
Sustainability & Growth Initiatives: Adoption of green chemistry metrics and ISO 14001 certification.
- Green chemistry scorecard implementation
- ISO 14001 environmental management
- Energy‑efficiency retrofit of reactors
8. Nanjing Chemlin Chemical Industry Co., Ltd.
Headquarters: Nanjing, China
Key Offering: Bulk chiral amine production with flexible quality options
Chemlin’s robust supply chain and rapid response capabilities serve both domestic and export markets.
Sustainability & Growth Initiatives: Implementation of zero‑emission manufacturing and renewable energy sourcing.
- Zero‑emission production lines
- Renewable electricity contracts
- Carbon‑neutral certification pursuit
9. Sigma‑Aldrich (Merck KGaA)
Headquarters: Darmstadt, Germany
Key Offering: Research‑grade chiral amines and laboratory reagents
Sigma‑Aldrich’s global distribution network ensures timely delivery to research institutions and small‑scale manufacturers.
Sustainability & Growth Initiatives: Focus on sustainable packaging and reduced solvent waste.
- Biodegradable packaging solutions
- Solvent‑recycling programs
- Supplier sustainability audits
10. Sigma‑Aldrich (Merck KGaA)
Headquarters: Darmstadt, Germany
Key Offering: High‑purity chiral intermediates for API development
Merck’s integrated R&D and production capabilities allow it to support large‑scale pharma projects with stringent quality requirements.
Sustainability & Growth Initiatives: Investment in renewable energy and carbon‑neutral manufacturing.
- Renewable energy procurement
- Carbon‑offset initiatives
- Life‑cycle assessment of chiral amine production
Download FREE Sample Report: (S)-1-Cyclohexylethylamine (CAS 17430-98-7) Market – View in Detailed Research Report
Get Full Report: (S)-1-Cyclohexylethylamine (CAS 17430-98-7) Market – View in Detailed Research Report
Market Outlook
Over the next decade, the (S)-1‑cyclohexylethylamine market is expected to maintain a steady trajectory driven by the continued emphasis on enantiomerically pure drugs and the expansion of chiral chemistry research. The convergence of regulatory demands, advanced synthesis technologies, and a growing portfolio of chiral drug candidates will keep the demand for high‑purity intermediates robust.
Emerging Trends
- Rapid adoption of biocatalytic synthesis routes that lower cost and environmental impact.
- Integration of AI‑driven process optimization for chiral amine production.
- Increasing demand for chiral intermediates in agrochemical development, particularly for selective herbicides and fungicides.
- Expansion of multi‑source supply chains to mitigate single‑source risks.
Segment Analysis
| Segment Category | Sub‑Segments | Key Insights |
| By Type |
|
Pharmaceutical Grade leads prominently owing to its essential compliance with rigorous purity standards demanded in the synthesis of enantiomerically pure pharmaceuticals. This segment thrives on the increasing complexity of drug molecules requiring precise stereochemistry to ensure therapeutic efficacy and minimize adverse effects, positioning it as the cornerstone for innovative treatments in the sector. |
| By Application |
|
Pharmaceutical Intermediates dominates as the primary avenue, where the compound serves as a vital building block for constructing complex chiral structures in active pharmaceutical ingredients. Its utility in enabling stereoselective reactions supports the development of next‑generation therapeutics targeting specific biological pathways, underscoring its indispensable role in advancing medicinal chemistry. |
| By End User |
|
Pharmaceutical Companies are at the forefront, leveraging the compound’s properties for scalable production of stereospecific drugs. This end‑user group drives innovation through extensive R&D, integrating the amine into synthesis routes for treatments addressing chronic diseases, thereby solidifying their leadership in demand patterns. |
| By Production Method |
|
Asymmetric Synthesis spearheads this category with its advantages in delivering consistently high enantiomeric purity at commercial scales. This method aligns seamlessly with green chemistry principles, reducing waste and enhancing process efficiency, making it the go‑to choice for manufacturers aiming for sustainable and cost‑optimized production of high‑value chiral amines. |
| By Distribution Channel |
|
Direct Sales commands the lead by offering tailored supply solutions, stringent quality assurances, and responsive logistics critical for time‑sensitive pharmaceutical projects. This channel fosters strong manufacturer‑customer partnerships, enabling just‑in‑time deliveries and customized packaging, which are pivotal for maintaining uninterrupted production flows in high‑stakes applications. |
Competitive Landscape
The market is dominated by a concentrated group of established fine‑chemical and chiral‑chemistry manufacturers, primarily based in China, Europe, and the United States. Leading players such as BASF SE, Evonik Industries AG, Jiangsu Hengrui Medicine Co., Ltd., and Shandong Xinhua Pharmaceutical Co., Ltd. leverage large‑scale synthesis capabilities and regulatory compliance frameworks to supply both domestic and international markets. European manufacturers bring advanced process‑chemistry expertise and cGMP‑compliant production to the market, catering to high‑purity pharmaceutical‑grade demand. The competitive dynamics are further shaped by the stringent quality requirements of end‑use pharmaceutical customers, which favor suppliers with robust analytical capabilities and documented optical purity (ee%) specifications.
In addition to the large‑scale producers, a number of specialized chiral‑chemistry and custom‑synthesis companies play an increasingly important role in supplying (S)-1‑cyclohexylethylamine to research institutions, contract development and manufacturing organizations (CDMOs), and specialty chemical customers. Companies such as Alfa Chemistry, TCI Chemicals, and Acros Organics (Thermo Fisher Scientific) supply catalog‑grade material to academic and industrial researchers globally. Chinese fine‑chemical manufacturers including Hangzhou Dayangchem Co., Ltd. and Nanjing Chemlin Chemical Industry Co., Ltd. have expanded their chiral amine portfolios in recent years, competing on cost efficiency while meeting international purity standards. The market remains fragmented at the lower volume, research‑grade tier, while the pharmaceutical bulk supply segment is more consolidated. Capacity expansions in China and increasing regulatory scrutiny in Western markets continue to shape the competitive dynamics of this niche but strategically important chiral intermediate.
Regional Analysis
North America dominates the (S)-1‑cyclohexylethylamine market due to its advanced pharmaceutical sector and robust research infrastructure. The region benefits from high demand in chiral synthesis applications, particularly for developing enantiomerically pure drugs. Leading pharmaceutical companies leverage this compound as a key intermediate in asymmetric synthesis and as a resolving agent for high‑purity separations. Strong regulatory frameworks ensure quality standards, fostering trust among end‑users. Innovation hubs in the US drive custom synthesis services, with focus on sustainable production methods. The market sees steady growth from expanding biotech firms exploring novel therapeutics. Supply chain efficiencies and proximity to major end‑markets enhance competitiveness. Investments in green chemistry align with environmental regulations, positioning North America as a hub for high‑value applications. Collaborations between academia and industry accelerate adoption in peptide synthesis and agrochemical intermediates. Overall, the region’s mature ecosystem supports premium pricing and consistent demand.
Europe holds a strong position in the (S)-1‑cyclohexylethylamine market, driven by its world‑class chemical industry clusters in Germany and Switzerland. High expertise in organic synthesis supports demand from pharmaceutical and agrochemical sectors. Stringent EU regulations promote high‑purity chiral compounds, enhancing market quality. Custom manufacturing thrives through collaborations between fine‑chemical specialists and drug developers. The region’s focus on innovation in catalysis and biocatalysis improves production efficiency. Steady investments in R&D facilities bolster applications in advanced therapeutics. Proximity to major pharma markets ensures efficient distribution and responsive supply chains. Sustainability initiatives align with green chemistry trends, attracting eco‑conscious buyers. Overall, Europe’s technical prowess maintains competitive edge in premium segments.
Asia‑Pacific emerges as a dynamic growth area for the compound, propelled by expanding manufacturing capabilities in China and India. Cost‑effective production scales meet rising global demand for chiral intermediates. Rapid pharma sector growth, especially generics and APIs, increases usage in synthesis processes. Local innovation centers develop efficient enantioselective methods, reducing reliance on imports. Government incentives for chemical parks foster infrastructure development. Supply chain integration with downstream users enhances market penetration. Challenges such as quality standardization are being addressed through international certifications. The region’s volume‑driven approach positions it for significant expansion in both domestic and export markets.
South America shows emerging interest in the compound, primarily through Brazil’s growing pharmaceutical industry. Demand stems from local drug formulation and biotech startups focusing on chiral technologies. Import dependency persists, but domestic production initiatives gain traction. Regional collaborations with global suppliers introduce advanced synthesis capabilities. Agrochemical applications support agricultural advancements. Infrastructure improvements aid logistics, while regulatory harmonization attracts investments. The market’s potential lies in expanding healthcare access and research partnerships, driving gradual adoption.
Middle East & Africa is nascent for the compound, with demand linked to developing pharma sectors in South Africa and Gulf countries. Focus areas include API manufacturing and research institutions exploring chiral chemistry. Investments in specialty chemical zones promote local synthesis. Partnerships with international firms bridge technology gaps. Challenges include limited infrastructure, but oil‑funded diversifications open opportunities. Gradual market maturation is expected as healthcare expands and regulatory frameworks strengthen.
Frequently Asked Questions
What is the current market size of (S)-1‑Cyclohexylethylamine (CAS 17430‑98‑7) Market?
-> Global (S)-1‑Cyclohexylethylamine (CAS 17430‑98‑7) market was valued at USD 28.4 million in 2025 and is expected to reach USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.
Which key companies operate in (S)-1‑Cyclohexylethylamine (CAS 17430‑98‑7) Market?
-> Key players include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, among others.
What are the key growth drivers of (S)-1‑Cyclohexylethylamine (CAS 17430‑98‑7) Market?
-> Key growth drivers include expanding demand for enantiomerically pure compounds in pharmaceutical synthesis, regulatory requirements for single‑enantiomer drugs over racemic mixtures, growing investment in chiral chemistry research, and rising adoption as a resolving agent and ligand precursor.
Which region dominates the market?
-> North America dominates the market, while Asia‑Pacific is the fastest‑growing region.
What are the emerging trends?
-> Emerging trends include advancements in asymmetric synthesis, increased use in pharmaceutical and agrochemical development, and focus on high enantiomeric purity for drug discovery.
- Top 10 Companies in the Aluminum Cake Market (2026): Market Leaders Powering Global Aluminum Supply - August 1, 2026
- Top 10 Companies in the Global Acepromazine Market (2026): Market Leaders Driving Veterinary Sedation - August 1, 2026
- Top 10 Companies in the Heavy Liquid Paraffin Market (2026): Market Leaders Powering Global Demand - August 1, 2026